- United Kingdom
- /
- Biotech
- /
- LSE:OXB
High Growth Tech Stocks In The UK Featuring Keywords Studios And Two More
Reviewed by Simply Wall St
The UK market has faced challenges recently, with the FTSE 100 index experiencing a decline following weak trade data from China, highlighting concerns over global economic recovery and its impact on commodity-linked companies. In this environment, high-growth tech stocks such as Keywords Studios offer potential opportunities for investors seeking resilience and innovation amidst broader market uncertainties.
Top 10 High Growth Tech Companies In The United Kingdom
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Gaming Realms | 11.57% | 22.07% | ★★★★★☆ |
STV Group | 13.15% | 46.78% | ★★★★★☆ |
Altitude Group | 23.46% | 27.56% | ★★★★★☆ |
Facilities by ADF | 52.00% | 144.70% | ★★★★★☆ |
LungLife AI | 100.61% | 100.97% | ★★★★★☆ |
Redcentric | 4.89% | 63.79% | ★★★★★☆ |
Windar Photonics | 63.60% | 126.92% | ★★★★★☆ |
Beeks Financial Cloud Group | 22.12% | 36.94% | ★★★★★☆ |
Oxford Biomedica | 21.00% | 98.44% | ★★★★★☆ |
Vinanz | 113.60% | 125.86% | ★★★★★☆ |
Click here to see the full list of 49 stocks from our UK High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Keywords Studios (AIM:KWS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Keywords Studios plc offers creative and technical services to the video game industry globally, with a market capitalization of £1.97 billion.
Operations: Keywords Studios generates revenue through three main segments: Create (€365.56 million), Engage (€180.43 million), and Globalize (€261.61 million).
Despite a challenging backdrop, Keywords Studios is poised to capitalize on robust industry trends with its forecasted revenue growth of 10.2% per year, outpacing the UK market's 3.5%. The company's strategic investments in research and development are substantial, aiming to fuel innovation and maintain competitive advantage in the gaming and tech services sectors. Recent events underscore this direction; notably, Keywords Studios was recently acquired for £2 billion by a consortium led by EQT Private Capital Asia and CPP Investments, reflecting confidence in its future trajectory. This acquisition not only values Keywords at approximately 15.9 times its adjusted EBITDA but also sets a strong foundation for future growth under new ownership—expected to be finalized in Q4 2024—with an emphasis on expanding its service offerings and market reach.
- Click to explore a detailed breakdown of our findings in Keywords Studios' health report.
Review our historical performance report to gain insights into Keywords Studios''s past performance.
Oxford Biomedica (LSE:OXB)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Oxford Biomedica plc is a contract development and manufacturing organization specializing in delivering therapies globally, with a market capitalization of £448.83 million.
Operations: Oxford Biomedica focuses on delivering therapies globally, generating revenue primarily from its platform segment, which accounts for £97.24 million.
Oxford Biomedica, navigating through a challenging yet opportunistic landscape, is poised for significant growth with its revenue expected to surge by 21% annually. This outpaces the broader UK market's growth of 3.6%, underscoring the company’s robust position in biotechnology. Despite current unprofitability, Oxford Biomedica's strategic focus on R&D is evident as it channels substantial funds into innovation—R&D expenses have notably increased to foster groundbreaking therapies in gene and cell therapy sectors. The firm recently projected an impressive earnings growth of 98.4% per year, signaling potential profitability within three years. Moreover, recent executive appointments and reaffirmed financial guidance for 2024 emphasize a steadfast commitment to advancing its technological capabilities and market presence.
- Navigate through the intricacies of Oxford Biomedica with our comprehensive health report here.
Gain insights into Oxford Biomedica's past trends and performance with our Past report.
Pinewood Technologies Group (LSE:PINE)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pinewood Technologies Group PLC is a cloud-based dealer management software provider serving the automotive industry both in the United Kingdom and internationally, with a market cap of £280.95 million.
Operations: Pinewood Technologies Group generates revenue primarily through its software solutions, with the software segment contributing £22.62 million. The company focuses on providing cloud-based dealer management systems to the automotive sector across various regions.
Pinewood Technologies Group, amidst a challenging tech landscape, demonstrates robust growth prospects with its revenue expected to rise by 20.1% annually, outstripping the UK market's average of 3.6%. This growth is supported by a significant contract with Marshall Motor Group to implement Pinewood's systems across approximately 120 dealerships, underscoring the company’s expansion and adoption in competitive sectors. Despite a downturn in net income from GBP 26.9 million to GBP 5 million in the first half of the year, Pinewood maintains strong R&D commitments which are crucial for sustaining innovation and competitiveness in software solutions. The forecasted annual earnings growth of 24.7% positions it well for future profitability and market presence enhancement.
Make It Happen
- Get an in-depth perspective on all 49 UK High Growth Tech and AI Stocks by using our screener here.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About LSE:OXB
Oxford Biomedica
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
High growth potential and good value.